

## Drug Monograph

Drug/Drug **Alcortin™A (hydrocortisone acetate, iodoquinol, and**  
 Class: **aloe vera leaf) gel/ Topical Corticosteroid Combination**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
<b>Dosage Forms:</b>	Alcortin® A is a gel that contains 2% (20 mg) hydrocortisone acetate, 1% (10 mg) iodoquinol, and 1% (10 mg) aloe polysaccharide per gram.	
<b>Manufacturer:</b>	Sonar Products, Inc., Carlstadt, NJ 07072 for Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253	
<b>Indications:</b>	Alcortin® A is a prescription drug indicated for: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo.	
<b>Costs:</b>	\$3.71 per gram of Alcortin® A WholesaleAcquisitionCost	
<b>Summary of Findings:</b>	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).	
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Under Solicitation
	<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer, PharmD  
 Date: August 14, 2014